Skip to main content
Brie Carter Photo
Brie Carter

Brie Carter

GrafaTV Presenter & Finance Editor

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.

Articles by Brie Carter

Grafa

Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.

Read more: Lexaria Bioscience welcomes FDA approval of Eli Lilly’s Foundayo as oral GLP-1 market expands
Grafa

FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).

Read more: FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010
Grafa
Technology

ASML shares fall as U.S. lawmakers propose further curbs on China exports

Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.

Read more: ASML shares fall as U.S. lawmakers propose further curbs on China exports